AI assistant
Aprea Therapeutics, Inc. — Director's Dealing 2021
Feb 16, 2021
35269_dirs_2021-02-16_0e683b43-333b-4365-93d5-00af113a3da1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aprea Therapeutics, Inc. (APRE)
CIK: 0001781983
Period of Report: 2020-12-28
Reporting Person: Redmile Group, LLC (10% Owner)
Reporting Person: Green Jeremy (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-12-28 | Common Stock | S | 494137 | $5.58 | Disposed | 1774581 | Indirect |
| 2020-12-28 | Common Stock | S | 5863 | $5.80 | Disposed | 1768718 | Indirect |
Footnotes
F1: These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC ("Redmile") and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.